Jennifer Litton

Jennifer Litton is a breast oncologist and hereditary breast cancer specialist who has led PARP inhibitor studies in BRCA-mutated breast cancer patients, including contributions to trials that enrolled male patients with BRCA2 germline mutations. She led the OlympiAD and veliparib neoadjuvant trials and has advocated for mandatory inclusion of male breast cancer patients in germline-stratified clinical trials. Her research has also examined the distinct BRCA1-associated versus BRCA2-associated male breast cancer profiles and optimal surveillance strategies.